Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | IDH1 mutant |
Therapy | Vorasidenib |
Indication/Tumor Type | oligodendroglioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 mutant | oligodendroglioma | predicted - sensitive | Vorasidenib | Phase III | Actionable | In a Phase III trial, Vorasidenib (AG-881) treatment improved progression-free survival (27.7 months vs 11.1 months, HR=0.39, p=0.000000067) and time to next intervention (not reached vs 17.8 months, HR=0.26, p=000000019) in patients with oligodendroglioma or astrocytoma harboring IDH1/2 mutations compared to placebo (J Clin Oncol 41, 2023 (suppl 17; abstr LBA1); NCT04164901). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. | Full reference... |